GlassScriptPhysician profile
Troy Moser
NPI 1942667258
$3,300.04
in general payments reported to CMS, 2019-2025
29 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $885 · 2023: $700 · 2024: $901 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $369.21 | 2021-2025 | |
| Pfizer INC. | $285.30 | 2021-2025 | |
| Lilly USA, LLC | $279.82 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $277.76 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $250.65 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $230.96 | 2021-2024 | Airsupra, Farxiga |
| Abbott Laboratories | $197.10 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $129.94 | 2021-2024 | Verquvo, Vaxelis, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $95.33 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.62 | 2021-2022 | |
| Exact Sciences Corporation | $80.33 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.13 | 2022-2023 | |
| Astellas Pharma US INC | $65.83 | 2023-2024 | Veozah |
| Dexcom, INC. | $54.06 | 2023-2024 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2022-2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $44.93 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $39.45 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.52 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.76 | 2021-2023 | Trulance |
| Lundbeck LLC | $20.15 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $16.98 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.46 | 2022 | |
| Amarin Pharma, INC. | $16.06 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.51 | 2021 | |
| Axsome Therapeutics, INC. | $14.89 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $12.15 | 2021 | |
| Eisai INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.